CL2021001810A1 - Combinación de dextrometorfano y bupropión para el tratamiento de depresión - Google Patents

Combinación de dextrometorfano y bupropión para el tratamiento de depresión

Info

Publication number
CL2021001810A1
CL2021001810A1 CL2021001810A CL2021001810A CL2021001810A1 CL 2021001810 A1 CL2021001810 A1 CL 2021001810A1 CL 2021001810 A CL2021001810 A CL 2021001810A CL 2021001810 A CL2021001810 A CL 2021001810A CL 2021001810 A1 CL2021001810 A1 CL 2021001810A1
Authority
CL
Chile
Prior art keywords
dextromethorphan
bupropion
depression
treatment
combination
Prior art date
Application number
CL2021001810A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Antecip Bioventures Ii Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antecip Bioventures Ii Llc filed Critical Antecip Bioventures Ii Llc
Publication of CL2021001810A1 publication Critical patent/CL2021001810A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se divulgan las formas de dosificación, sistemas de suministro de fármacos y métodos relacionados con la liberación sostenida de dextrometorfano o efectos terapéuticos mejorados. Típicamente, bupropión o un compuesto relacionado se administra por vía oral a un ser humano a ser tratado con o que es tratado con dextrometorfano.
CL2021001810A 2019-01-07 2021-07-07 Combinación de dextrometorfano y bupropión para el tratamiento de depresión CL2021001810A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962789488P 2019-01-07 2019-01-07
US201962789446P 2019-01-07 2019-01-07
US201962789451P 2019-01-07 2019-01-07
US201962789431P 2019-01-07 2019-01-07

Publications (1)

Publication Number Publication Date
CL2021001810A1 true CL2021001810A1 (es) 2022-03-04

Family

ID=71521902

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021001810A CL2021001810A1 (es) 2019-01-07 2021-07-07 Combinación de dextrometorfano y bupropión para el tratamiento de depresión

Country Status (16)

Country Link
EP (1) EP3908270A4 (es)
JP (1) JP2022516361A (es)
KR (1) KR20210110654A (es)
CN (4) CN114712357A (es)
AU (2) AU2020207261B2 (es)
BR (1) BR112020025902A2 (es)
CA (2) CA3126062C (es)
CL (1) CL2021001810A1 (es)
CO (1) CO2021008988A2 (es)
CR (1) CR20210368A (es)
EC (1) ECSP21051833A (es)
IL (1) IL284663A (es)
MX (1) MX2021008247A (es)
PE (1) PE20212249A1 (es)
SG (1) SG11202106392RA (es)
WO (1) WO2020146412A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11433067B2 (en) 2013-11-05 2022-09-06 Antecip Bioventures Ii Llc Bupropion as a modulator of drug activity
KR20230113787A (ko) 2020-12-01 2023-08-01 안테씨프 바이오벤쳐스 투 엘엘씨 우울증 환자의 자살 위험 감소를 위한 부프로피온 및덱스트로메토르판
WO2023004064A1 (en) * 2021-07-21 2023-01-26 Antecip Bioventures Ii Llc Treatment of depression
WO2023225511A1 (en) * 2022-05-17 2023-11-23 Antecip Bioventures Ii Llc Treatment of depression
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
US11844797B1 (en) 2023-04-20 2023-12-19 Antecip Bioventures Ii Llc Combination of dextromethorphan and bupropion for treating depression

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007092329A2 (en) * 2006-02-03 2007-08-16 Avanir Pharmaceuticals Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
CN104812378B (zh) * 2012-10-11 2017-12-01 Ix生物制药有限公司 固体剂型
CN104955483A (zh) * 2013-01-30 2015-09-30 法莫斯医疗公司 用低剂量药剂治疗抑郁症和其它疾病
CA3154845C (en) * 2013-11-05 2023-02-28 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds and dextromethorphan
US10512643B2 (en) * 2013-11-05 2019-12-24 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
TW202231278A (zh) * 2014-09-14 2022-08-16 美商阿瓦尼爾製藥股份有限公司 用於治療失智症中躁動行為之包含右旋美索芬(dextromethorphan)化合物及奎尼丁(quinidine)的藥學組成物
AU2015350559C1 (en) * 2014-11-21 2019-07-11 Antecip Bioventures Ii Llc Methods of modulating drug plasma levels using erythrohydroxybupropion

Also Published As

Publication number Publication date
CN112437659A (zh) 2021-03-02
CN114712358A (zh) 2022-07-08
AU2020207261B2 (en) 2023-04-13
CA3126062A1 (en) 2020-07-16
ECSP21051833A (es) 2021-11-18
CO2021008988A2 (es) 2021-09-09
CN114712357A (zh) 2022-07-08
EP3908270A1 (en) 2021-11-17
KR20210110654A (ko) 2021-09-08
CA3223187A1 (en) 2020-07-16
SG11202106392RA (en) 2021-07-29
BR112020025902A2 (pt) 2021-07-13
CA3126062C (en) 2024-02-06
MX2021008247A (es) 2021-08-16
CR20210368A (es) 2021-12-10
WO2020146412A1 (en) 2020-07-16
AU2023204348A1 (en) 2023-07-27
EP3908270A4 (en) 2022-02-16
CN114712356A (zh) 2022-07-08
JP2022516361A (ja) 2022-02-25
PE20212249A1 (es) 2021-11-24
AU2020207261A1 (en) 2021-07-08
IL284663A (en) 2021-08-31
CN112437659B (zh) 2022-04-12

Similar Documents

Publication Publication Date Title
CL2021001810A1 (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
AR057946A1 (es) Formulacion de zonisamida de liberacion sostenidda
CL2020002512A1 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak.
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
EA201890507A1 (ru) Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
AR119159A1 (es) Tratamientos de angioedema
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
CL2021003034A1 (es) Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton
AR117614A1 (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
CO2022008001A2 (es) Métodos para el tratamiento de trastornos depresivos
ES2563068T3 (es) Tratamiento de esclerosis múltiple (MS) con Campath-1H
AR041891A1 (es) Empleo de resveratrol para la preparacion de un medicamento util para el tratamiento de infecciones causadas por el virus de la influenza
AR065917A1 (es) Composicion farmaceutica en forma de tableta sublingual que comprende un antiinflamatorio no esteroideo y un analgesico opiaceo para el manejo del dolor
ECSP066836A (es) Piperazinas derivadas de úrea para el tratamiento de la endometrosis
UY39510A (es) Compuestos macrocíclicos y métodos para usarlos
CL2021003312A1 (es) Composición que comprende pridopidina y un análogo de la misma para el tratamiento de la enfermedad de huntington y síntomas de la misma.
AR109760A1 (es) Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinson
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
PL425832A1 (pl) Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico
AR109693A1 (es) Formulaciones de liberación inmediata de oprozomib